<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560232</url>
  </required_header>
  <id_info>
    <org_study_id>17-028</org_study_id>
    <nct_id>NCT03560232</nct_id>
  </id_info>
  <brief_title>Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens</brief_title>
  <official_title>A Randomized Controlled Trial Assessing Noninferiority of Three Antimicrobial Regimens for the Treatment of Grade III Open Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Health Ohio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Health Ohio</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate noninferiority of three different empiric antimicrobial regimens compared to
      the traditional antimicrobial regimen for the management of grade III open fractures as well
      as evaluate outcomes among these groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Per the EAST practice management guidelines, an open fracture is defined as one in which the
      fracture fragments communicate with the environment through a break in the skin. The presence
      of an open fracture, either isolated or as part of a multiple injury complex, increases the
      risk of infection and soft tissue complications. Open fractures are further classified into
      Grade I - Grade III fractures per the Gustilo Classification. Grade III fractures are those
      with the highest likelihood of contamination and infection with infection rates ranging from
      10% to 42%.

      EAST guidelines currently recommend systemic gram positive coverage for all open fractures
      with the addition of gram negative coverage for all Grade III fractures. Antibiotics should
      be initiated as soon as possible following the injury and should be continued for 72 hours
      after the injury or not greater than 24 hours after soft tissue coverage was obtained.
      Traditionally, patients received the combination of Cefazolin and Gentamicin as the preferred
      prophylactic antibiotic regimen, despite the need for multiple antibiotics and the risk of
      nephrotoxicity associated with aminoglycosides. Whether there is clinically a more ideal
      prophylactic antibiotic available remains to be seen. This proposed research initiative is
      intended to evaluate several antibiotic regimens with similar spectrums of activity to see if
      there is an equally effective single agent with minimal nephrotoxicity associated with its
      use. In selecting the study antibiotics to be utilized in the protocol, available information
      was obtained regarding timing of antibiotics, organisms identified by culture results, and
      any studies available on specific antibiotic regimens. In regards to timing, there is
      evidence to support that time to antibiotics and time to the operating room may be more
      important than the particular antibiotic itself. Additionally, a recent study from 2015
      looked at the organisms identified from culture results for Grade I through Grade III
      fractures in Germany. The vast majority of cultures obtained were gram positive organisms,
      even in the Grade III fractures, and included Staphylococcus epidermidis, Staphylococcus
      aureus, Staphylococcus capitis, various Streptococcus species, Enterococcus faecium and
      Corynebacterium. Interestingly, the only gram negative organism identified in the study was
      Escherichia coli. Lastly, when trying to identify antibiotic specific studies, a recent study
      was identified looking at Ceftriaxone as the agent of choice, while limiting the use of
      vancomycin and aminoglycosides. The conclusion of the study showed a significant decrease in
      vancomycin and aminoglycosides administered with no increase in infection rates.

      Here at St. Elizabeth Youngstown Hospital, the investigator's current trauma and orthopedics
      practice management guideline has been reviewed and changed multiple times in the past
      several years. For the vast majority of time, the recommendation has been to use the
      traditional cefazolin/gentamicin combination. However, several cases of nephrotoxicity led to
      some hesitation in utilizing this regimen. Therefore, for a short time period,
      piperacillin/tazobactam was being used for all Grade III fractures instead. At present
      however, due to conflicting concerns regarding antimicrobial stewardship with utilizing broad
      spectrum piperacillin/tazobactam with the nephrotoxicity concerns of gentamicin, the approved
      guideline utilizes cefazolin/gentamicin for patients under 65 years of age and
      piperacillin/tazobactam for all patients greater than or equal to 65 years of age. This study
      aims to evaluate non-inferiority of ampicillin/sulbactam, ceftriaxone, and
      piperacillin/tazobactam when compared to the traditional regimen of cefazolin/gentamicin for
      grade III open fractures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-surgical site wound infections</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome for this study is the number of post-surgical site wound infections, defined as initiation of antibiotics for surgical-site infection and/or need for surgical debridement of site. The acceptable infection rate per Trauma Practice Management Guidelines states a rate less than 20%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute kidney injury</measure>
    <time_frame>Hospital admission</time_frame>
    <description>Incidence of acute kidney injury during hospital admission will be collected and compared to the other antibiotic regimens.
Acute kidney injury is defined as (per KDIGO guidelines):
An increase in SCr by 0.3 mg/dL within 48 hours OR
Increase in SCr to 1.5 times baseline within the previous 7 days OR
Urine volume less than 0.5 mL/kg/h for 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average cost of antibiotic therapy per patient</measure>
    <time_frame>Hospital admission</time_frame>
    <description>Cost per patient of each antibiotic therapy will be calculated and compared to the other antibiotic regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to antibiotic therapy</measure>
    <time_frame>Hospital admission</time_frame>
    <description>Time from arrival to receiving first dose of antibiotic therapy will be collected (Goal within 30 minutes of arrival).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Open Fracture</condition>
  <condition>Post-Op Wound Infection</condition>
  <arm_group>
    <arm_group_label>Cefazolin + Gentamicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>[Cefazolin]
Initial dose:
Cefazolin 2g IV x1 dose (patient weight &lt; 120kg)
Cefazolin 3g IV x1 dose (patient weight &gt;/= 120kg)
Subsequent dose:
Cefazolin 2g IV every 8 hrs (CrCl &gt;/= 40 mL/min)
Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)
Cefazolin 2g IV every 24 hrs (CrCl &lt; 20 mL/min)
Duration:
24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first
[Gentamicin]
Initial dose:
If Patient age &lt;/= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)
If Patient age &gt;80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)
Subsequent dose:
Pharmacy Consult to dose gentamicin
Duration:
24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial dose:
Ceftriaxone 2g IV x1 dose
Subsequent dose:
Ceftriaxone 2g IV every 24 hours
Duration:
One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ampicillin/Sulbactam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial dose:
Ampicillin/Sulbactam 3g IV x1 dose
Subsequent dose:
Ampicillin/Sulbactam 3g IV every 6 hours (CrCl &gt;/= 30 mL/min)
Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)
Ampicillin/Sulbactam 3g IV every 24 hours (CrCl &lt;15 mL/min)
Duration:
24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperacillin/Tazobactam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial dose:
Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes
Subsequent dose:
Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl &gt;/= 20 mL/min)
Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl &lt; 20 mL/min)
Duration:
24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin + Gentamicin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with known Penicillin allergy will receive:
[Clindamycin]
Initial dose:
Clindamycin 900mg IV x1 dose
Subsequent dose:
Clindamycin 600mg IV every 8 hours
Duration:
24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first
[Gentamicin]
Initial dose:
If Patient age &lt;/= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)
If Patient age &gt;80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)
Subsequent dose:
Pharmacy Consult to dose gentamicin
Duration:
24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftriaxone</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Ceftriaxone</arm_group_label>
    <other_name>Rocephin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin/sulbactam</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Ampicillin/Sulbactam</arm_group_label>
    <other_name>Unasyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/tazobactam</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Piperacillin/Tazobactam</arm_group_label>
    <other_name>Zosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin + Gentamicin</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Cefazolin + Gentamicin</arm_group_label>
    <other_name>Ancef + Garamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin + Gentamicin</intervention_name>
    <description>See arm description</description>
    <arm_group_label>Clindamycin + Gentamicin</arm_group_label>
    <other_name>Cleocin + Garamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age great than/equal to 18 years

          -  Diagnosis of Grade III open fracture

        Exclusion Criteria:

          -  Water-borne injury

          -  Farm-related injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie I Rine, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>MercyHealth Youngstown</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul T Miller, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>MercyHealth Youngstown</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tyson T Schrickel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MercyHealth Youngstown</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Drew, DO</last_name>
    <role>Study Chair</role>
    <affiliation>MercyHealth Youngstown</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Gemmel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>MercyHealth Youngstown</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chad W Donley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MercyHealth Youngstown</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison R Lauver, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>MercyHealth Youngstown</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chad W Donley, MD</last_name>
    <phone>330-480-3667</phone>
    <email>chad_donley@mercy.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allison R Lauver, PharmD</last_name>
    <phone>330-480-3829</phone>
    <email>allison_lauver@mercy.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph Warren Hospital</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Donley, MD</last_name>
      <phone>330-841-4029</phone>
      <email>chad_donley@mercy.com</email>
    </contact>
    <investigator>
      <last_name>Chad Donley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth Youngstown Hospital</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>44501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Donley, MD</last_name>
      <phone>330-480-3667</phone>
      <email>chad_donley@mercy.com</email>
    </contact>
    <investigator>
      <last_name>Chad Donley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gustilo RB, Mendoza RM, Williams DN. Problems in the management of type III (severe) open fractures: a new classification of type III open fractures. J Trauma. 1984 Aug;24(8):742-6.</citation>
    <PMID>6471139</PMID>
  </reference>
  <reference>
    <citation>Hoff WS, Bonadies JA, Cachecho R, Dorlac WC. East Practice Management Guidelines Work Group: update to practice management guidelines for prophylactic antibiotic use in open fractures. J Trauma. 2011 Mar;70(3):751-4. doi: 10.1097/TA.0b013e31820930e5.</citation>
    <PMID>21610369</PMID>
  </reference>
  <reference>
    <citation>Lack WD, Karunakar MA, Angerame MR, Seymour RB, Sims S, Kellam JF, Bosse MJ. Type III open tibia fractures: immediate antibiotic prophylaxis minimizes infection. J Orthop Trauma. 2015 Jan;29(1):1-6. doi: 10.1097/BOT.0000000000000262. Erratum in: J Orthop Trauma. 2015 Jun;29(6):e213.</citation>
    <PMID>25526095</PMID>
  </reference>
  <reference>
    <citation>Otchwemah R, Grams V, Tjardes T, Shafizadeh S, Bäthis H, Maegele M, Messler S, Bouillon B, Probst C. Bacterial contamination of open fractures - pathogens, antibiotic resistances and therapeutic regimes in four hospitals of the trauma network Cologne, Germany. Injury. 2015 Oct;46 Suppl 4:S104-8. doi: 10.1016/S0020-1383(15)30027-9.</citation>
    <PMID>26542854</PMID>
  </reference>
  <reference>
    <citation>Rodriguez L, Jung HS, Goulet JA, Cicalo A, Machado-Aranda DA, Napolitano LM. Evidence-based protocol for prophylactic antibiotics in open fractures: improved antibiotic stewardship with no increase in infection rates. J Trauma Acute Care Surg. 2014 Sep;77(3):400-7; discussion 407-8; quiz 524. doi: 10.1097/TA.0000000000000398.</citation>
    <PMID>25159242</PMID>
  </reference>
  <reference>
    <citation>Lenarz CJ, Watson JT, Moed BR, Israel H, Mullen JD, Macdonald JB. Timing of wound closure in open fractures based on cultures obtained after debridement. J Bone Joint Surg Am. 2010 Aug 18;92(10):1921-6. doi: 10.2106/JBJS.I.00547. Epub 2010 Jul 21.</citation>
    <PMID>20660225</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open Fracture</keyword>
  <keyword>Wound Infection</keyword>
  <keyword>Antimicrobial Prophylaxis</keyword>
  <keyword>Cefazolin</keyword>
  <keyword>Gentamicin</keyword>
  <keyword>Ceftriaxone</keyword>
  <keyword>Ampicillin/Sulbactam</keyword>
  <keyword>Clindamycin</keyword>
  <keyword>Piperacillin/tazobactam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Open</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Sultamicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

